The global personalized medicine biomarkers market size accounted for USD 19.05 billion in 2024, grew to USD 22.04 billion in 2025 and is expected to be worth around USD 82.08 billion by 2034, registering a CAGR of 15.73% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Personalized Medicine Biomarkers Market
5.1. COVID-19 Landscape: Personalized Medicine Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Personalized Medicine Biomarkers Market, By Application
8.1. Personalized Medicine Biomarkers Market, by Application, 2024-2034
8.1.1 Early Detection/Screening
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Diagnosis
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Treatment Selection
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Monitoring
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Personalized Medicine Biomarkers Market, By Indication
9.1. Personalized Medicine Biomarkers Market, by Indication, 2024-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Neurology
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Diabetes
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Cardiology
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Personalized Medicine Biomarkers Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by January (2021-2034)
10.1.2. Market Revenue and Forecast, by February (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by January (2021-2034)
10.1.3.2. Market Revenue and Forecast, by February (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by January (2021-2034)
10.1.4.2. Market Revenue and Forecast, by February (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by January (2021-2034)
10.2.2. Market Revenue and Forecast, by February (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by January (2021-2034)
10.2.3.2. Market Revenue and Forecast, by February (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by January (2021-2034)
10.2.4.2. Market Revenue and Forecast, by February (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by January (2021-2034)
10.2.5.2. Market Revenue and Forecast, by February (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by January (2021-2034)
10.2.6.2. Market Revenue and Forecast, by February (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by January (2021-2034)
10.3.2. Market Revenue and Forecast, by February (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by January (2021-2034)
10.3.3.2. Market Revenue and Forecast, by February (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by January (2021-2034)
10.3.4.2. Market Revenue and Forecast, by February (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by January (2021-2034)
10.3.5.2. Market Revenue and Forecast, by February (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by January (2021-2034)
10.3.6.2. Market Revenue and Forecast, by February (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by January (2021-2034)
10.4.2. Market Revenue and Forecast, by February (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by January (2021-2034)
10.4.3.2. Market Revenue and Forecast, by February (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by January (2021-2034)
10.4.4.2. Market Revenue and Forecast, by February (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by January (2021-2034)
10.4.5.2. Market Revenue and Forecast, by February (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by January (2021-2034)
10.4.6.2. Market Revenue and Forecast, by February (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by January (2021-2034)
10.5.2. Market Revenue and Forecast, by February (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by January (2021-2034)
10.5.3.2. Market Revenue and Forecast, by February (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by January (2021-2034)
10.5.4.2. Market Revenue and Forecast, by February (2021-2034)
Chapter 11. Company Profiles
11.1. Laboratory Corporation of America Holding
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Quest Diagnostics Incorporated
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Agilent Technologies, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Genome Medical, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Coriell Life Sciences.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Thermo Fisher Scientific Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. NeoGenomics Laboratories
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. FOUNDATION MEDICINE, INC.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Illumina, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Guardant Health
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample